Alivus Life Sciences Ltd Forensic Report - SOIC x StockScans Report

as of Aug 2026

Alivus Life Sciences carries a clean audit record, but the label hides real leverage: a ₹700 crore rated working-capital facility and supplier-finance arrangements sit outside reported borrowings. Cash has collapsed from ₹512.3 crore to 1.98 crore in four years while dividends ran ahead of free cash flow, and the 2024 change of control from Glenmark to Nirma brought a full board reset, accelerated ESOP vesting, and a ₹27.24 crore MD pay package that public institutions voted against.

Key findings

  1. A ₹700 crore working-capital facility sits outside reported borrowings Major - India Ratings rated Alivus's bank loan facilities at ₹700 crore as of 16 Sep 2025, comprising fund-based and non-fund-based working capital limits. The FY2025-26 standalone financial statements disclose supplier finance arrangements with no material extension of payment terms, no collateral, and no fee. Yet CARO Clause (ix) for FY2024-25 states the company "has no loans or other borrowings from any lender," and management framed the company as "debt-free" in the Q1 FY27 earnings call without qualification.
  2. Cash reserves fell from ₹512.3 crore to 1.98 crore in four years Major - Cash and cash equivalents fell from ₹512.3 crore at 31 March 2022 to 1.98 crore at 31 March 2026. Free cash flow turned negative to ₹227 crore in FY23 as dividends rose to ₹385.9 crore from ₹128.7 crore and capex rose to ₹170.2 crore from ₹132.2 crore. The Board paid interim dividends of ₹257.31 crore in March 2023 and ₹275.69 crore in October 2023.
  3. Nirma's takeover brought a board reset, accelerated ESOPs, and a ₹27.24 crore MD package Major - Glenmark sold 75% of paid-up capital to Nirma under a share purchase agreement dated 21 September 2023, with 55% transferred on 6 March 2024 and 20% on 12 March 2024. On 6 March 2024, three directors resigned and three new directors were appointed the same day, and the Board approved acceleration of vesting of 6,11,465 unvested ESOP options effective 16 March 2024. Dr. Yasir Rawjee's FY2023-24 remuneration was ₹27.24 crore, and public institutional shareholders voted 24.0209% against his reappointment at the 25 September 2024 AGM.
  4. Revenue recognition is a recurring Key Audit Matter with one customer at a third of revenue Minor - The auditor identified revenue recognition as a Key Audit Matter in FY2022, FY2023, FY2024, and FY2025, citing risk of overstatement or premature recognition. Revenue from one major customer was ₹847.01 crore in FY2022, ₹690.46 crore in FY2023, ₹716.47 crore in FY2024, ₹780.51 crore in FY2025, and ₹742.04 crore in FY2026. The company stated in FY2023 that no bad debts had occurred and no material receivables were outstanding for more than six months, so no expected credit loss assessment was performed.
  5. Tax and customs demands are widening while capital commitments tripled Minor - Standalone capital commitments rose to ₹105.68 crore at 31 March 2026 from ₹33.1 crore at 31 March 2025. The Income Tax Department issued an assessment order dated 20 Mar 2026 for AY 2023-24 with a demand of Rs. 2,60,67,810. A Customs order dated 19 Aug 2025 imposed a redemption fine of Rs. 3,00,00,000 and penalties for alleged mis-classification of goods.
  6. Five unqualified audit opinions, one recurring audit-trail exception Minor - The Independent Auditor's Report expressed an unqualified opinion for each of FY2021-22 through FY2025-26. The Section 143(3)(b) proper-books statement for FY2023-24, FY2024-25, and FY2025-26 each carried an exception: the audit trail feature was not enabled at the database level to log direct data changes, though no instance of tampering was found where the feature was enabled. The internal financial controls opinion was unmodified in each of the five years.
  7. Related-party dealings were arm's-length trade with Glenmark, now ended Clean - Shareholders approved material related party transactions with Glenmark Pharmaceuticals at limits of ₹1,075 crore, then ₹1,025 crore, then ₹512.5 crore across successive approvals from October 2021 to March 2025. The Company had no contracts or arrangements with Related Parties under Section 188(1) in FY2025-26, and Form AOC-2 was not applicable. Glenmark ceased to be holding company with effect from 6 March 2024.
  8. No operating subsidiaries; only a disclosed minority stake in a captive renewable entity Clean - The Company had no subsidiaries, joint ventures, or associate companies during FY2021-22, FY2022-23, FY2023-24, and FY2025-26. On 2 April 2025, Alivus announced acquisition of a minimum 9.21% stake in Torrent Urja 19 Private Limited for captive renewable energy compliance, while promoter Nirma Ltd is acquiring a minimum 16.99% stake in the same entity.

What to watch

Bottom line: This is a disclosed and audited record with five clean opinions and no fraud flags. The risk is presentational and structural: a "debt-free" claim that excludes ₹700 crore of rated working-capital limits, cash that has been paid out faster than the business generates it, and a governance reset whose pay decisions drew a notable public institutional vote against one reappointment. Watch the tax and customs outcomes and whether the GPL revenue decline reverses.